Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. 2001

H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
Department of Gastroenterological Surgery, UllevÄl University Hospital, Oslo, Norway.

Human umbilical vein endothelial cells (HUVEC) have previously been shown to synthesize the functional terminal pathway of complement based on the detection by radioimmunoassay of the terminal complement complex (TCC) on coincubated agarose beads. In addition, C7 secretion by these cells in amounts comparable to C3, as well as C7 mRNA, has recently been demonstrated. However, it has not been possible to detect C5-6 and C8 in the fluid phase, and only trace amounts of soluble C9. Against this background we examined whether mRNA for the remaining terminal complement factors was present in HUVEC. By the use of reverse transcription (RT)-polymerase chain reaction (PCR) and Northern blot the presence of mRNA for complement factors C5, C6, C8 and C9 was demonstrated.

UI MeSH Term Description Entries
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003182 Complement C5 C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX. C5 Complement,Complement 5,Complement C5, Precursor,Complement Component 5,Precursor C5,Pro-C5,Pro-complement 5,C5, Complement,C5, Precursor,C5, Precursor Complement,Complement, C5,Component 5, Complement,Precursor Complement C5,Pro C5,Pro complement 5
D003183 Complement C6 A 105-kDa serum glycoprotein with significant homology to the other late complement components, C7-C9. It is a polypeptide chain cross-linked by 32 disulfide bonds. C6 is the next complement component to bind to the membrane-bound COMPLEMENT C5B in the assembly of MEMBRANE ATTACK COMPLEX. It is encoded by gene C6. C6 Complement,Complement 6,Complement Component 6,C6, Complement,Complement, C6,Component 6, Complement
D003185 Complement C8 A 150-kDa serum glycoprotein composed of three subunits with each encoded by a different gene (C8A; C8B; and C8G). This heterotrimer contains a disulfide-linked C8alpha-C8gamma heterodimer and a noncovalently associated C8beta chain. C8 is the next component to bind the C5-7 complex forming C5b-8 that binds COMPLEMENT C9 and acts as a catalyst in the polymerization of C9. C8 Complement,Complement 8,Complement Component 8,Complement Component C8 alpha,Complement Component C8 alpha Chain,Complement Component C8 beta,Complement Component C8 beta Chain,Complement Component C8 gamma,Complement Component C8 gamma Chain,C8, Complement,Complement, C8,Component 8, Complement
D003186 Complement C9 A 63-kDa serum glycoprotein encoded by gene C9. Monomeric C9 (mC9) binds the C5b-8 complex to form C5b-9 which catalyzes the polymerization of C9 forming C5b-p9 (MEMBRANE ATTACK COMPLEX) and transmembrane channels leading to lysis of the target cell. Patients with C9 deficiency suffer from recurrent bacterial infections. C9 Complement,Complement 9,Complement Component 9,C9, Complement,Complement, C9,Component 9, Complement
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
June 1991, Scandinavian journal of immunology,
H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
October 1986, Scandinavian journal of immunology,
H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
April 1970, Immunology,
H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
November 1990, Scandinavian journal of immunology,
H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
January 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
June 1987, Scandinavian journal of immunology,
H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
September 2006, The Journal of chemical physics,
H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
March 1989, Clinical immunology and immunopathology,
H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
January 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
H Langeggen, and K E Berge, and P Macor, and F Fischetti, and F Tedesco, and G Hetland, and K Berg, and E Johnson
November 1971, European journal of immunology,
Copied contents to your clipboard!